This retrospective study used real-world data to estimate the impact of SGLT2 inhibitors and GLP-1 receptor agonists, used singly or in combination with each other, on all-cause mortality and cardiorenal outcomes in people with type 2 diabetes. Data from 2010 to 2023 were obtained from TriNetX, a collaborative health research network spanning 14 countries, with most participants living in the US.
Data on approximately 186 000 GLP-1 RA recipients, 143 000 SGLT2 inhibitor recipients and 108 000 recipients of the two drug classes combined were compared with 1.8 million individuals who received neither drug. Participants were propensity-score-matched for age, gender, ischaemic heart disease, hypertension, heart failure, chronic kidney disease (CKD) and HbA1c.
In the survival analysis, over 5 years, SGLT2 inhibitors reduced the risk of all-cause mortality by 51%. Hospitalisation, myocardial infarction, angina, heart disease, heart failure, atrial fibrillation, stroke, lower limb amputation and CKD were also reduced by 9–31%. GLP-1 RAs reduced the risk of all-cause mortality by 53% and cardiorenal outcomes by 10–34%.
Combining the two therapies resulted in a 75% reduction in all-cause mortality and 16–41% reductions in cardiorenal outcomes. When comparing combination with individual therapies, significant reductions in mortality and cardiorenal outcomes were observed.
While acknowledging the limitations of the retrospective design and a potential lack of data completeness in this real-world database, the authors conclude that SGLT2 inhibitors and GLP-1 RAs are more effective than other diabetes medications in terms of preventing mortality, cardiovascular and renal outcomes in people with type 2 diabetes, and that combining the therapies has additive benefits. These findings should be confirmed in randomised controlled trials of monotherapy versus combination therapy.
Amid accumulating evidence of benefits with new diabetes drugs, Vinod Patel asks whether the costs can be justified.
9 Nov 2023